Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN, Wagner F, Hüser A, Igel J, Joseph D, Hilbert J, Schoelch C, Padula SJ, Steffgen J. Albach FN, et al. Among authors: hilbert j. Eur J Clin Pharmacol. 2018 Feb;74(2):161-169. doi: 10.1007/s00228-017-2362-8. Epub 2017 Nov 10. Eur J Clin Pharmacol. 2018. PMID: 29127458 Free PMC article. Clinical Trial.
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
Schwabe C, Rosenstock B, Doan T, Hamilton P, Dunbar PR, Eleftheraki AG, Joseph D, Hilbert J, Schoelch C, Padula SJ, Steffgen J. Schwabe C, et al. Among authors: hilbert j. J Clin Pharmacol. 2018 Dec;58(12):1566-1577. doi: 10.1002/jcph.1278. Epub 2018 Aug 16. J Clin Pharmacol. 2018. PMID: 30113724 Free PMC article. Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A, Koenen R, Hilbert J, Blatchford J, Kappeler D, Benediktus E, Wood C, Gupta A. Fowler A, et al. Among authors: hilbert j. J Clin Pharmacol. 2017 Nov;57(11):1444-1453. doi: 10.1002/jcph.947. Epub 2017 Jun 13. J Clin Pharmacol. 2017. PMID: 28609567 Clinical Trial.
Pharmacokinetics and dose proportionality of loratadine.
Hilbert J, Radwanski E, Weglein R, Luc V, Perentesis G, Symchowicz S, Zampaglione N. Hilbert J, et al. J Clin Pharmacol. 1987 Sep;27(9):694-8. doi: 10.1002/j.1552-4604.1987.tb03090.x. J Clin Pharmacol. 1987. PMID: 2960701 Clinical Trial.
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.
Döhner H, Müller-Tidow C, Lübbert M, Fiedler W, Krämer A, Westermann J, Bug G, Schlenk RF, Krug U, Goeldner RG, Hilbert J, Taube T, Ottmann OG. Döhner H, et al. Among authors: hilbert j. Br J Haematol. 2019 May;185(3):583-587. doi: 10.1111/bjh.15563. Epub 2018 Nov 19. Br J Haematol. 2019. PMID: 30450591 Free article. Clinical Trial. No abstract available.
Loratadine: multiple-dose pharmacokinetics.
Radwanski E, Hilbert J, Symchowicz S, Zampaglione N. Radwanski E, et al. Among authors: hilbert j. J Clin Pharmacol. 1987 Jul;27(7):530-3. doi: 10.1002/j.1552-4604.1987.tb03061.x. J Clin Pharmacol. 1987. PMID: 2958516
Pharmacokinetics of loratadine in patients with renal insufficiency.
Matzke GR, Halstenson CE, Opsahl JA, Hilbert J, Perentesis G, Radwanski E, Zampaglione N. Matzke GR, et al. Among authors: hilbert j. J Clin Pharmacol. 1990 Apr;30(4):364-71. doi: 10.1002/j.1552-4604.1990.tb03607.x. J Clin Pharmacol. 1990. PMID: 2140371
178 results